Verastem, Inc. - שולי רווח נקי ממכירות VSTM

סמל מסחרי של verastem.com (VSTM)

Operational risks for Verastem, Inc. (VSTM) are linked to laboratory capacity constraints, as evidenced by the company's net margin ratio, where the figure stands at -178.40. Stability is maintained through partnerships with research centers and the successful trials of avutometinib for ovarian cancer. FDA approval and patent protection will help curb capital expenditure, minimizing chart volatility.

verastem.com (VSTM) - רווחיות מכירות נקייה מ-04.07.2022 עד 19.11.2026

Verastem Inc - פילוחים אנליטיים ומדדי מפתח (VSTM)

- מחיר מניה וקונצנזוס הערכת שווי:
אנליטיקה מסכמת של החברה:Verastem Corp - VSTM
מוצרים מוגמרים של Verastem Oncology

Verastem, Inc. focuses on completing clinical trials for targeted oncology drugs to transition to the market sales stage. The net profit margin trend reflects the share of profit after all deductions, allowing investors to identify abnormal R&D expenses and assess the fundamental value stability of the asset prior to the full commercialization of its products.